Summary & Overview
HCPCS C1817: Septal Defect Implant System, Intracardiac
HCPCS Level II code C1817 identifies an intracardiac septal defect implant system, a device used to close or repair defects in the cardiac septum. The code matters nationally because septal defect closure is a common structural heart intervention affecting device utilization, payer coverage policies, and hospital resource planning. Implant systems for atrial or ventricular septal defects have implications for procedural coding accuracy, device reimbursement, and post-procedure surveillance.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for septal defect implant procedures, typical sites of service (cardiac catheterization lab or operating room in inpatient and outpatient settings), and the role of HCPCS Level II coding for device identification. The publication outlines common billing modifiers and other administrative elements when available, and summarizes what to expect in national payer coverage approaches. Where input data is not provided, the report notes that those specific items are not available.
Billing Code Overview
HCPCS Level II code C1817 describes a septal defect implant system, intracardiac. This device-based service involves implantation of a device to close or repair defects in the cardiac septum.
-
Service type: Implantation of an intracardiac septal defect closure system
-
Typical site of service: Cardiac catheterization lab or operating room (inpatient or outpatient cardiac surgical setting)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with a secundum atrial septal defect (ASD) or other intracardiac septal defect identified by echocardiography and cardiology evaluation. The patient presents with exertional dyspnea, recurrent respiratory infections in children, right heart enlargement on imaging, or paradoxical embolic events. After diagnostic workup including transthoracic and transesophageal echocardiography (often with bubble study) and cardiac catheterization as indicated, the interventional cardiology team schedules a transcatheter closure using a septal defect implant system (C1817).
The clinical workflow includes pre-procedure evaluation (history, informed consent, review of antiplatelet/anticoagulant therapy), anesthesia planning (general anesthesia or monitored anesthesia care), vascular access (typically femoral venous), intracardiac imaging guidance (transesophageal or intracardiac echocardiography), catheter delivery of the implant, device deployment and confirmation of position and seal, post-deployment hemodynamic and imaging assessment, and recovery with post-procedure monitoring. Typical sites of service are the hospital catheterization laboratory, hybrid operating room, or an ambulatory surgical center with appropriate cardiovascular capabilities. Expected post-procedure care includes short inpatient observation for adults or overnight stay for pediatric patients, antiplatelet therapy per device labeling, and follow-up echocardiography to confirm device position and absence of residual shunt.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|